Precigen, Inc. (PGEN) Builds Commercial Stage With Global Regulatory Support
Precigen Inc. (NASDAQ:PGEN) is one of Goldman Sachs’ top penny stock picks. On January 20, Precigen Inc. (NASDAQ:PGEN) received a significant boost after a consensus paper authored by 16 physicians recommended its flagship drug, PAPZIMEOS, as the standard of care for adults with recurrent respiratory papillomatosis.
The recommendation is a significant boost as it asserts a potential shift from surgical intervention to treating underlying HPV infection that causes recurrent respiratory papillomatosis. The medical condition affects the respiratory tract and is caused by a chronic HPV-6 or HPV-11 infection.
“The speed and agility with which the authors evaluated the evidence and aligned on a recommended first-line treatment and new standard of care for adults with RRP underscores both the unmet need in this disease,” said Helen Sabzevari, President and CEO of Precigen.
Precigen has already transitioned into a commercial-stage company with the US approval of PAPZIMEOS in August 2025. It has become the first and only FDA treatment for adults with RRP. The company has also received a significant boost from the European Medicines Agency, which has validated the Marketing Authorization Application for PAPZIMEOS for the treatment of adults with RRP.
Precigen, Inc. (NASDAQ:PGEN) is a clinical-stage biopharmaceutical company focused on developing gene and cellular therapies to treat complex, high-need diseases in immuno-oncology, autoimmune disorders, and infectious diseases.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
US Treasury yield curve approaches inversion! Is the bond market questioning the outlook for the US economy?
The U.S. Treasury yield curve is rapidly approaching the inversion threshold—the spread between the 10-year and 2-year yields has narrowed to historic lows, and bank stocks have responded with a technical correction. This warning signal, regarded as a "hard rule" for recession, is tearing apart market consensus: some are betting the curve will soon invert, while others firmly believe economic resilience will mitigate the risk. Amid ongoing Federal Reserve rate hikes, the outcome of this bond market game may reshape the narrative logic of the entire asset market.
From ICU to KTV! The Polarized "AI Narrative" Leaves Investors "Exhausted"
In just two weeks, the Nasdaq 100 experienced an extreme rollercoaster: first losing $600 billion in market value due to “AI threat” concerns, then rebounding to reclaim $3 trillion thanks to the viral Meta assistant. Analysts believe that market sentiment is swinging violently between fear and greed, detached from fundamentals. The turmoil has driven Nvidia’s valuation to a ten-year low, intensified the bull-bear divide, and the high volatility driven by narratives has become a long-term norm for investors. This week, Micron will release its financial report; regardless of the outcome, the sharp swings in market sentiment are unlikely to subside.
Weekly Preview: Micron (MU.US) earnings test the quality of AI infrastructure, OpenAI and White House AI meeting resonance, PCE and Nonfarm Payrolls set the tone for October interest rates
This week, the market's focus will shift from politics and product launches to financial reports and macroeconomic data.
"Over 5% 10-Year US Treasury Yield" Fails to Crush AI Investment Frenzy—Is the Real "AI Kill Line" an Inverted Yield Curve?
The bond market is gradually sending warning signals to the economy, indicating that the Federal Reserve's series of interest rate hikes will begin to shift market sentiment, making people increasingly concerned that the US economy may fall into stagnation.
Crypto prices
More
